ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

Press/Media

Period9 Jul 2021

Media coverage

1

Media coverage

  • TitleABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date9/07/21
    PersonsSang Hoon Lee
View all 1
View less